To see all protocols that comply with the WHO Essential Medicine List 

Following discussion at March 2023 cancer genetics reference committee meeting, this protocol was discontinued as no longer clinically useful. Refer to additional clinical information document ID 3665 Polyposis of unknown aetiology - surveillance strategy instead.

The information contained in this document is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to care or treatment. Any clinician seeking to apply or consult this document is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information sources. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page


First approved:
Discontinued:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/1423

29 Mar 2024